Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1R,2S)-2-(1-methylhydrazino)-1-phenylbutan-1-ol
-
(1R,2S)-2-(1-methylhydrazino)-1-phenylpentan-1-ol
-
(1R,2S)-2-(1-methylhydrazino)-1-phenylpropan-1-ol
-
(2-methylprop-2-en-1-yl)hydrazine
-
-
(2-phenylprop-2-en-1-yl)hydrazine
(2E)-3-chloroprop-2-en-1-amine
-
-
(2E)-3-fluoro-4-phenoxybut-2-en-1-amine
-
-
(2E)-4-phenoxybut-2-en-1-amine
-
-
(2Z)-3-chloroprop-2-en-1-amine
-
-
(2Z)-3-fluoro-4-phenoxybut-2-en-1-amine
-
-
(2Z)-4-phenoxybut-2-en-1-amine
-
-
(4-[[(2E)-4-amino-2-fluorobut-2-en-1-yl]oxy]phenyl)(pyrrolidin-1-yl)methanone
-
-
(Z)-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride
1,4-diamino-2-chloro-2-butene
1,6-diamino-2,4-hexadiyne
1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(1-methylhydrazino)-ethanol
-
1-(2,5-dihydro-1H-pyrrol-3-yl)isoquinoline
-
-
1-(2-(3-chlorophenyl)-2-methoxyethyl)-1-methylhydrazine
-
1-(2-chlorophenyl)-2-(1-methylhydrazino)ethanol
-
1-(2-phenylpropyl)hydrazine
-
1-(3,5-diethoxypyridin-4-yl)methanamine dihydrochloride
1-(3-methoxyphenyl)-2-(1-methylhydrazino)ethanol
-
1-(4-chlorophenyl)-2-(1-methylhydrazino)ethanol
-
1-(4-fluorophenyl)-2-(1-methylhydrazino)ethanol
-
1-(4-methoxyphenyl)-2-(1-methylhydrazino)ethanol
-
1-(isoquinolin-1-ylcarbonyl)pyrrolidine-2-carboxamide
-
-
1-benzyl-1-methylhydrazine
-
1-ethyl-1-(2-phenylethyl)hydrazine
-
1-ethyl-1-[2-(3,4,5-trimethoxyphenyl)ethyl]hydrazine
-
1-ethyl-1-[2-(4-methoxyphenyl)ethyl]hydrazine
-
1-ethyl-2-[2-(4-fluorophenyl)prop-2-en-1-yl]hydrazine
-
-
1-isobutyl-1-(2-phenylethyl)hydrazine
-
1-isobutyl-1-[2-(4-methoxyphenyl)ethyl]hydrazine
-
1-methyl-1-(2-phenylethyl)hydrazine
-
1-methyl-1-(2-phenylpropyl)hydrazine
-
1-methyl-1-(3-phenylpropyl)hydrazine
-
1-[2-(2,3,4-trimethoxyphenyl)ethyl]-1-methylhydrazine
-
1-[2-(2,5-dimethoxyphenyl)ethyl]-1-methylhydrazine
-
1-[2-(2-chlorophenyl)ethyl]-1-methylhydrazine
-
1-[2-(2-fluorophenyl)ethyl]-1-methylhydrazine
-
1-[2-(2-methoxyphenyl)ethyl]-1-methylhydrazine
-
1-[2-(3,4,5-trimethoxyphenyl)ethyl]-1-methylhydrazine
-
1-[2-(3,4-dimethoxyphenyl)ethyl]-1-methylhydrazine
-
1-[2-(3-chlorophenyl)ethyl]-1-methylhydrazine
-
1-[2-(3-fluorophenyl)-2-methoxyethyl]-1-methylhydrazine
-
1-[2-(3-methoxyphenyl)ethyl]-1-methylhydrazine
-
1-[2-(4-chlorophenyl)-2-methoxyethyl]-1-methylhydrazine
-
1-[2-(4-chlorophenyl)ethyl]-1-methylhydrazine
-
1-[2-(4-fluorophenyl)-2-methoxyethyl]-1-methylhydrazine
-
1-[2-(4-fluorophenyl)ethyl]-1-methylhydrazine
-
1-[2-(4-fluorophenyl)prop-2-en-1-yl]-2-methylhydrazine
-
-
1-[2-(4-methoxyphenyl)ethyl]-1-methylhydrazine
-
1-[2-benzyloxy-2-(4-methoxyphenyl)ethyl]-1-methylhydrazine
-
1-[2-methoxy-1-(3-tolyl)ethyl]-1-methylhydrazine
-
1-[2-methoxy-1-(4-methoxyphenyl)ethyl]-1-methylhydrazine
-
1-[2-methoxy-2-(1-naphthyl)ethyl]-1-methylhydrazine
-
1-[2-methoxy-2-(2,3,4-trimethoxyphenyl)ethyl]-1-methylhydrazine
-
1-[2-methoxy-2-(2-naphthyl)ethyl]-1-methylhydrazine
-
1-[2-methoxy-2-(3-methoxyphenyl)ethyl]-1-methylhydrazine
-
1-[3,5-bis(ethylsulfanyl)pyridin-4-yl]methanamine dihydrochloride
-
-
1-[3,5-bis(tert-butylsulfanyl)pyridin-4-yl]methanamine dihydrochloride
-
-
1-[3-(benzyloxy)-5-ethoxypyridin-4-yl]methanamine dihydrochloride
-
-
2,2-dimethyl-2-(1-methylhydrazino)-1-phenylethanol
-
2,6-bis(1-methylethoxy)benzylamine
-
-
2,6-bis(2-hydroxyethoxy)benzylamine
-
-
2,6-bis(3-hydroxypropoxy)benzylamine
-
-
2,6-bis(4-hydroxybutoxy)benzylamine
-
-
2,6-bis(ethoxymethyl)benzylamine
-
-
2,6-bis(methoxymethyl)benzylamine
-
-
2,6-dibutoxybenzylamine
-
-
2,6-dibutylbenzylamine
-
-
2,6-diethoxybenzylamine
-
-
2,6-diethylbenzylamine
-
-
2,6-dihydroxybenzylamine
-
-
2,6-dimethoxybenzylamine
-
-
2,6-dipropoxybenzylamine
-
-
2,6-dipropylbenzylamine
-
-
2-(1-isobutylhydrazino)-1-phenylethanol
-
2-(1-methylhydrazino)-1-(2,3,4-trimethoxyphenyl)ethanol
-
2-(1-methylhydrazino)-1-(2-naphthyl)ethanol
-
2-(1-methylhydrazino)-1-phenylethanol
-
2-(2,5-dihydro-1H-pyrrol-3-yl)pyridine
-
-
2-(4-methoxyphenyl)-1-(1-methylhydrazino)-2-propanol
-
2-(4-[2-[2-(acetylamino)-2,3-dihydro-1,3-thiazol-4-yl]ethyl]phenyl)-N-[amino(imino)methyl]acetamide
-
-
2-(aminooxy)-1-(3,4-dimethoxyphenyl)ethanol
-
-
2-(aminooxy)-1-phenylethanol
-
-
2-(methylamino)ethanethiol
-
reversible inhibition
2-(methylthio)ethylamine
-
weak irreversible inhibitor
2-([[4-(1,1-dimethylpropyl)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide
-
-
2-amino-N-[2-fluoro-3-(trifluoromethyl)benzyl]acetamide
-
-
2-amino-N-[2-fluoro-5-(trifluoromethyl)benzyl]acetamide
-
-
2-amino-N-[3-fluoro-5-(trifluoromethyl)benzyl]acetamide
-
-
2-amino-N-[4-fluoro-3-(trifluoromethyl)benzyl]acetamide
-
-
2-ethylaminobenzylamine dihydrochloride
2-hydrazino-1-(3-methoxyphenyl)ethanol
-
2-hydrazino-1-(4-methoxyphenyl)ethanol
-
2-hydrazino-1-phenylethanol
-
2-hydroxymethylbenzylamine
-
-
2-methylaminobenzylamine dihydrochloride
2-[(biphenyl-4-ylacetyl)amino]pentanedioic acid
-
-
3,3'-[[4-(aminomethyl)pyridine-3,5-diyl]bis(oxy)]dipropan-1-ol dihydrochloride
-
-
3,3-bis(aminoethyl)-1-hydroxy-2-oxo-1-triazene
3-(1-piperidinyl)-4-aminomethylpyridine dihydrochloride hemihydrate
3-(2,5-dihydro-1H-pyrrol-3-yl)pyridine
-
-
3-(2-naphthyl)-3-pyrroline
-
0.2 mM, inactivation of BPAO by 3-aryl-3-pyrrolines
3-(4-methoxy-3-nitrophenyl)-3-pyrroline
-
0.015 mM, inactivation of BPAO by 3-aryl-3-pyrrolines
3-(4-methoxyphenyl)-2,5-dihydro-1H-pyrrole hydrochloride
-
0.4 mM, inactivation of BPAO by 3-aryl-3-pyrrolines
3-(4-methoxyphenyl)-N-methyl-5-(1H-pyrrol-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
-
3-amino-4-aminomethylpyridine dihydrochloride
-
-
3-aminopropanethiol
-
reversible inhibition
3-biphenyl-4-yl-2,5-dihydro-1H-pyrrole hydrochloride
-
0.1 mM, inactivation of BPAO by 3-aryl-3-pyrrolines
3-bromoprop-2-yn-1-amine
-
-
3-cycloheptylamino-4-aminomethylpyridine dihydrochloride monohydrate
3-cyclohexylamino-4-aminomethylpyridine dihydrochloride monohydrate
3-cyclohexylmethylamino-4-aminomethylpyridine dihydrochloride monohydrate
3-cyclopentylamino-4-aminomethylpyridine dihydrochloride hemihydrate
3-cyclopropylamino-4-aminomethylpyridine dihydrochloride sesquihydrate
3-ethylamino-4-aminomethylpyridine dihydrochloride
3-methylamino-4-aminomethylpyridine dihydrochloride
3-naphthalen-1-yl-2,5-dihydro-1H-pyrrole hydrochloride
-
0.4 mM, inactivation of BPAO by 3-aryl-3-pyrrolines
3-phenyl-3-pyrroline
-
0.4 mM, inactivation of BPAO by 3-aryl-3-pyrrolines
3-[(1-methylethyl)amino]-4-aminomethylpyridine dihydrochloride
3-[2-(3-methoxyphenyl)ethyl]-2,5-dihydro-1H-pyrrole
-
-
4,4'-[[4-(aminomethyl)pyridine-3,5-diyl]bis(oxy)]dibutan-1-ol dihydrochloride
-
-
4-(2,5-dihydro-1H-pyrrol-3-yl)-N,N-dimethylaniline hydrochloride
-
0.4 mM, inactivation of BPAO by 3-aryl-3-pyrrolines
4-(2-naphthyloxy)but-2-yn-1-amine
-
-
4-(4-methoxyphenoxy)but-2-yn-1-amine
-
-
4-(4-methylphenoxy)but-2-yn-1-amine
-
-
4-(4-nitrophenoxy)but-2-yn-1-amine
-
-
4-(aminomethyl)-2-benzyl-5-(ethylamino)pyridazin-3(2H)-one
-
below 10% inhibition at 0.5 mM
4-(aminomethyl)-2-methyl-5-(morpholin-4-yl)pyridazin-3(2H)-one
-
93% inhibition at 0.5 mM
4-(aminomethyl)-2-methyl-5-(pyrrolidin-1-yl)pyridazin-3(2H)-one
-
below 10% inhibition at 0.5 mM
4-(aminomethyl)-5-(ethylamino)-2-methylpyridazin-3(2H)-one
-
13% inhibition at 0.5 mM
4-(aminomethyl)-N,N-diethylpyridazine-3,5-diamine
-
over 99% inhibition at 0.5 mM
4-(aminomethyl)-N,N'-bis(1-methylethyl)pyridine-3,5-diamine dihydrochloride
-
-
4-(aminomethyl)-N,N'-dibutylpyridine-3,5-diamine dihydrochloride
-
-
4-(aminomethyl)-N,N'-diethylpyridazine-3,5-diamine
-
-
4-(aminomethyl)-N,N'-diethylpyridine-3,5-diamine dihydrochloride
4-(aminomethyl)-N,N'-dimethylpyridine-3,5-diamine dihydrochloride
4-(aminomethyl)-N-butylpyridazin-3-amine
-
27% inhibition at 0.5 mM
4-(aminomethyl)-N-ethylpyridazin-3-amine
-
29% inhibition at 0.5 mM
4-(aminomethyl)-N-methylpyridazin-3-amine
-
47% inhibition at 0.5 mM
4-(aminomethyl)-N-methylpyridine-3,5-diamine dihydrochloride
-
-
4-(aminomethyl)-N-propylpyridazin-3-amine
-
44% inhibition at 0.5 mM
4-amino-3-hydroxy-N-(3-phenylpropyl)benzamide
-
-
4-aminobut-2-ynenitrile
-
-
4-bromo-N-[2-(hydroxyamino)-2-oxoethyl]benzamide
-
-
4-hydroxybenzylhydrazine
-
-
4-phenoxybut-2-yn-1-amine
-
-
4-[[(2E)-4-amino-2-fluorobut-2-en-1-yl]oxy]-N,N-dimethylbenzamide
-
-
4-[[(2E)-4-amino-2-fluorobut-2-en-1-yl]oxy]-N-(1-phenylethyl)benzamide
-
-
4-[[(2E)-4-amino-2-fluorobut-2-en-1-yl]oxy]-N-benzyl-N-methylbenzamide
-
-
4-[[(2E)-4-amino-2-fluorobut-2-en-1-yl]oxy]-N-benzylbenzamide
-
-
4-[[(2E)-4-amino-2-fluorobut-2-en-1-yl]oxy]-N-cyclohexylbenzamide
-
-
4-[[(2E)-4-amino-2-fluorobut-2-en-1-yl]oxy]-N-cyclopentylbenzamide
-
-
4-[[(2E)-4-amino-2-fluorobut-2-en-1-yl]oxy]benzamide
-
-
5-amino-2-hydroxy-N-(3-phenylpropyl)benzamide
-
-
alkylamino derivatives of 4-aminomethylpyridine
-
-
amikacin
-
about 60% residual activity at 1 mM
Br-
uncompetitive inhibitor with respect to the substrate amine and noncompetitive inhibitor with respect to dissolved oxygen
buta-2,3-dien-1-amine
-
-
Cl-
uncompetitive inhibitor with respect to the substrate amine and noncompetitive inhibitor with respect to dissolved oxygen
CuCl2
-
strong inhibition at 1 mM
cysteamine
-
reversible inhibition
EDTA
treatment with EDTA reduces the activity of wild type enzyme
extract from Taiwanofungus camphoratus
-
F-
uncompetitive inhibitor with respect to the substrate amine and noncompetitive inhibitor with respect to dissolved oxygen
geraniin
-
competitive inhibition. Inhibitory activities of 10.87%, 37.24%, 77.67%, and 95.77%, respectively, for 0.00066, 0.00164, 0.00328, and 0.00656 mM of geraniin
histamine
substrate inhibition; substrate inhibition
hydrazine
-
complete inhibition at 1 mM
I-
uncompetitive inhibitor with respect to the substrate amine and noncompetitive inhibitor with respect to dissolved oxygen
Iproniazid
-
nearly complete inhibition at 1 mM
kanamycin
-
about 70% residual activity at 1 mM
KCl
-
100 mM, 88% inhibition of dimeric and tetrameric enzyme
L-Lys
-
the presence of L-lysine during the oxidation of benzylamine results in time- and dose-dependent inhibition of SSAO activity, in a process that is dependent on the H2O2 formed during benzylamine oxidation
N,3-dihydroxy-2-[(2-naphthylsulfonyl)amino]butanamide
-
-
N-allyl-3-(4-methoxyphenyl)-5-(1H-pyrrol-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
-
N-ethyl-3-(4-methoxyphenyl)-5-(1H-pyrrol-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
-
N-[2-(hydroxyamino)-2-oxoethyl]-2-(2-methyl-1H-indol-3-yl)acetamide
-
-
N-[4-(2-[4-[(2-amino-1H-imidazol-5-yl)methyl]phenyl]ethyl)-1,3-thiazol-2-yl]acetamide
-
-
N-[4-[2-(4-carbamimidamidophenyl)ethyl]-5-(4-sulfamoylbenzyl)-1,3-thiazol-2-yl]acetamide
-
-
N-[4-[2-(4-[[amino(imino)methyl]amino]phenyl)ethyl]-1,3-thiazol-2-yl]acetamide
-
-
N6-(4-aminobut-2-ynyl)adenine
NaCl
-
100 mM, 88% inhibition of dimeric and tetrameric enzyme
Neocuproine
-
0.033 mM, 61% inhibition
nitric oxide
irreversible inhibitor
o-phenylenediamine
-
0.2 mM, 33% inhibition of dimeric enzyme, 26% inhibition of tetrameric enzyme
p-chloromercuriphenylsulfonate
-
0.1 mM, complete inhibition of enzyme from cultured aortic smooth muscle cells
rasagiline ethanedisulfonate
-
inhibits MAO-B
ruthenium(II) molecular wires
the enzyme is reversibly inhibited by molecular wires comprising a Ru(II) complex head group and an aromatic tail group joined by an alkane linker
-
sisomycin
-
about 45% residual activity at 1 mM
Sodium thioglycolate
-
slight
tobramycin
-
about 40% residual activity at 1 mM
[(2E)-3-fluoro-2-phenylprop-2-en-1-yl]hydrazine
-
-
[2-(2-methylphenyl)prop-2-en-1-yl]hydrazine
-
-
[2-(4-chlorophenyl)prop-2-en-1-yl]hydrazine
-
-
[2-(4-fluorophenyl)prop-2-en-1-yl]hydrazine
-
-
(2-phenylprop-2-en-1-yl)hydrazine
-
-
(2-phenylprop-2-en-1-yl)hydrazine
-
-
(Z)-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride
-
i.e. LJP 1586. Potent, specific, and orally available inhibitor of SSAO activity is an effective anti-inflammatory compound in vivo
(Z)-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride
-
i.e. LJP 1586. Potent, specific, and orally available inhibitor of SSAO activity is an effective anti-inflammatory compound in vivo
(Z)-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride
-
i.e. LJP 1586. Potent, specific, and orally available inhibitor of SSAO activity is an effective anti-inflammatory compound in vivo
1,4-diamino-2-butyne
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
1,4-diamino-2-butyne
-
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
1,4-diamino-2-butyne
-
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
1,4-diamino-2-butyne
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
1,4-diamino-2-chloro-2-butene
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
1,4-diamino-2-chloro-2-butene
-
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
1,4-diamino-2-chloro-2-butene
-
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
1,4-diamino-2-chloro-2-butene
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
1,4-phenanthroline
-
0.0075 mM, 41% inhibition
1,4-phenanthroline
-
0.33 mM, 65% inhibition
1,5-diamino-2-pentyne
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
1,5-diamino-2-pentyne
-
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
1,5-diamino-2-pentyne
-
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
1,5-diamino-2-pentyne
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
1,6-diamino-2,4-hexadiyne
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
1,6-diamino-2,4-hexadiyne
-
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
1,6-diamino-2,4-hexadiyne
-
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
1,6-diamino-2,4-hexadiyne
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
1-(3,5-diethoxypyridin-4-yl)methanamine dihydrochloride
-
1-(3,5-diethoxypyridin-4-yl)methanamine dihydrochloride
-
1-(3,5-diethoxypyridin-4-yl)methanamine dihydrochloride
-
-
2-Bromoethylamine
-
-
2-Bromoethylamine
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
2-Bromoethylamine
-
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
2-Bromoethylamine
-
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
2-Bromoethylamine
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
2-Bromoethylamine
-
irreversible inhibitor
2-ethylaminobenzylamine dihydrochloride
-
2-ethylaminobenzylamine dihydrochloride
-
2-ethylaminobenzylamine dihydrochloride
-
-
2-methylaminobenzylamine dihydrochloride
-
2-methylaminobenzylamine dihydrochloride
-
2-methylaminobenzylamine dihydrochloride
-
-
2-Phenylethylamine
substrate inhibition
2-Phenylethylamine
substrate inhibition
3,3-bis(aminoethyl)-1-hydroxy-2-oxo-1-triazene
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
3,3-bis(aminoethyl)-1-hydroxy-2-oxo-1-triazene
-
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
3,3-bis(aminoethyl)-1-hydroxy-2-oxo-1-triazene
-
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
3,3-bis(aminoethyl)-1-hydroxy-2-oxo-1-triazene
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
3-(1-piperidinyl)-4-aminomethylpyridine dihydrochloride hemihydrate
-
3-(1-piperidinyl)-4-aminomethylpyridine dihydrochloride hemihydrate
-
-
3-cycloheptylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cycloheptylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cycloheptylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
-
3-cyclohexylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cyclohexylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
-
3-cyclohexylmethylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cyclohexylmethylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cyclohexylmethylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
-
3-cyclopentylamino-4-aminomethylpyridine dihydrochloride hemihydrate
-
3-cyclopentylamino-4-aminomethylpyridine dihydrochloride hemihydrate
-
-
3-cyclopropylamino-4-aminomethylpyridine dihydrochloride sesquihydrate
-
3-cyclopropylamino-4-aminomethylpyridine dihydrochloride sesquihydrate
-
-
3-ethylamino-4-aminomethylpyridine dihydrochloride
-
3-ethylamino-4-aminomethylpyridine dihydrochloride
-
3-ethylamino-4-aminomethylpyridine dihydrochloride
-
-
3-methylamino-4-aminomethylpyridine dihydrochloride
-
3-methylamino-4-aminomethylpyridine dihydrochloride
-
3-methylamino-4-aminomethylpyridine dihydrochloride
-
-
3-[(1-methylethyl)amino]-4-aminomethylpyridine dihydrochloride
-
3-[(1-methylethyl)amino]-4-aminomethylpyridine dihydrochloride
-
-
4-(aminomethyl)-N,N'-diethylpyridine-3,5-diamine dihydrochloride
-
4-(aminomethyl)-N,N'-diethylpyridine-3,5-diamine dihydrochloride
-
4-(aminomethyl)-N,N'-diethylpyridine-3,5-diamine dihydrochloride
-
-
4-(aminomethyl)-N,N'-dimethylpyridine-3,5-diamine dihydrochloride
-
4-(aminomethyl)-N,N'-dimethylpyridine-3,5-diamine dihydrochloride
-
4-(aminomethyl)-N,N'-dimethylpyridine-3,5-diamine dihydrochloride
-
-
8-hydroxyquinoline
non-competitive inhibitor; non-competitive inhibitor; non-competitive inhibitor
8-hydroxyquinoline
-
strong inhibition at 1 mM
8-hydroxyquinoline
-
0.0075 mM, 27% inhibition
aminoguanidine
irreversible competitive inhibitor; irreversible competitive inhibitor; irreversible competitive inhibitor
aminoguanidine
irreversible inhibition
aminoguanidine
-
strongly inhibits adipocyte semicarbazide-sensitive amine oxidase and slightly reduces fat deposition in obese Zucker rats. Aminoguanidine may be useful for treating obesity via its SSAO blocking properties
aminoguanidine
-
isoform AO1 shows 18% residual activity at 0.1 mM, isoform AO2 shows 17% residual activity at 0.1 mM
aminoguanidine
-
irreversible inhibitor
benzylamine
substrate inhibition
benzylhydrazine
forms adducts with the TPQ cofactor, binding structure, overview
Cuprizone
-
copper chelating, 0.006 mM, 98% inhibition, competitive vs. benzylamine
Cuprizone
-
isoform AO1 shows 2% residual activity at 0.1 mM, isoform AO2 shows 1% residual activity at 0.1 mM
Cuprizone
-
competitive binding to enzyme copper is suggested
cyanide
-
0.1 mM, 76% inhibition
cyanide
-
uncompetitive vs. benzylamine, non-competititve vs. O2
diethyldithiocarbamate
-
3.3 mM, 74% inhibition
diethyldithiocarbamate
-
no inhibition
extract from Taiwanofungus camphoratus
-
-
-
extract from Taiwanofungus camphoratus
-
-
-
hydroxylamine
-
complete inhibition at 1 mM
hydroxylamine
-
elicits hypotension in the rat. This effect is due in part to its conversion to nitric oxide and in part to a hydralazine-like action involving SSAO inhibition
hydroxylamine
-
3.3 mM, 30% inhibition
isoniazid
-
nearly complete inhibition at 1 mM
isoniazid
-
0.2 mM, 42% inhibition of dimeric enzyme, 39% inhibition of tetrameric enzyme
isoniazid
-
isoform AO1 shows 14% residual activity at 0.1 mM, isoform AO2 shows 16% residual activity at 0.1 mM
N6-(4-aminobut-2-ynyl)adenine
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
N6-(4-aminobut-2-ynyl)adenine
-
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
N6-(4-aminobut-2-ynyl)adenine
-
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
N6-(4-aminobut-2-ynyl)adenine
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
NaN3
-
3.3 mM, 48% inhibition
NaN3
-
uncompetitive inhibition
NaN3
-
azide binds to Cu2+ ions, competitive inhibition vs. O2, uncompetitive vs. benzylamine
Phenelzine
-
Phenelzine
-
0.001 mM, complete inhibition of enzyme from cultured aortic smooth muscle cells
phenylhydrazine
-
-
phenylhydrazine
-
complete inhibition at 1 mM
phenylhydrazine
-
irreversible inactivation most likely due to hydrazone formation
Semicarbazide
-
nearly complete inhibition at 1 mM
Semicarbazide
-
0.2 mM, 49% inhibition of dimeric enzyme, 45% inhibition of tetrameric enzyme
Semicarbazide
causes significant decreases in the oxidative deamination activity of four among the five substrates catalyzed by SSAO
Semicarbazide
-
irreversible inhibitor. Pargyline + semicarbazide-induced reduction of fat deposition results from decreased food intake and from impaired MAO (EC 1.4.3.4) and SSAO-dependent lipogenic and antilipolytic actions of endogenous or alimentary amines
Semicarbazide
-
isoform AO1 shows 1% residual activity at 0.1 mM, isoform AO2 shows 2% residual activity at 0.1 mM
Semicarbazide
-
0.01 mM, complete inhibition of enzyme from cultured aortic smooth muscle cells
tranylcypromine
forms adducts with the TPQ cofactor, also termed (1R,2S)-rel-2-phenylcyclopropanamine, is a mixture of (1R,2S)-2-phenylcyclopropanamine and (1S,2R)-2-phenylcyclopropanamine, binding structure, overview
tranylcypromine
-
fully reversible competitive onhibitor
tryptamine
substrate inhibition
tryptamine
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
tryptamine
-
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
tryptamine
-
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
tryptamine
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
tyramine
irreversible inhibitor
tyramine
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
tyramine
-
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
tyramine
-
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
tyramine
substrate inhibition; substrate inhibition
tyramine
during the oxidation of these suicide substrates, the reversible formation of an enzyme-killer product complex occurs followed by an irreversible inactivation of the enzyme, typical of mechanism-based inactivation
additional information
-
not inhibited by MgCl2, MnCl2, CoCl2, ZnCl2, FeCl3, sodium azide, N-ethylmaleimide, and iodoacetate
-
additional information
-
3-pyrrolines are mechanism-based inactivators of the quinone-dependent amine oxidases but only substrates of the flavin-dependent amine oxidases
-
additional information
-
not inhibited by 2-aminoethanol and 2-(N,N-dimethylamino)ethanethiol
-
additional information
-
not inhibited by gentamycin
-
additional information
-
inhibitor synthesis and screening, overview
-
additional information
synthesis and in vitro activities of a series of VAP-1 selective inhibitors, molecular dynamics simulations and docking studies, pIC50 values, overview. Movements of Met211, Ser496, and especially Leu469 can enlarge the ligand-binding pocket, allowing larger ligands than those seen in the crystal structures to bind. Three-dimensional quantitative structure-activity relationship models for VAP-1 in comparison to MAOs, overview
-
additional information
-
synthesis and in vitro activities of a series of VAP-1 selective inhibitors, molecular dynamics simulations and docking studies, pIC50 values, overview. Movements of Met211, Ser496, and especially Leu469 can enlarge the ligand-binding pocket, allowing larger ligands than those seen in the crystal structures to bind. Three-dimensional quantitative structure-activity relationship models for VAP-1 in comparison to MAOs, overview
-
additional information
-
no effect: DTT or EDTA at 1 mM, 1,4-diamino-2-butanone, sodium azide or KCN
-
additional information
the enzyme activity is not significantly affected in the presence of 5 mM EDTA; the enzyme activity is not significantly affected in the presence of 5 mM EDTA
-
additional information
the enzyme activity is not significantly affected in the presence of 5 mM EDTA; the enzyme activity is not significantly affected in the presence of 5 mM EDTA
-
additional information
-
the enzyme activity is not significantly affected in the presence of 5 mM EDTA; the enzyme activity is not significantly affected in the presence of 5 mM EDTA
-
additional information
clorgyline and deprenyl do not significantly inhibit the activities
-
additional information
-
no inhibition by pargyline. SSAO activity remains unchanged during starvation
-
additional information
-
not inhibited by pargyline, clorgyline, and neocupine
-